Skip to main content
. Author manuscript; available in PMC: 2017 Aug 11.
Published in final edited form as: Melanoma Res. 2016 Jun;26(3):272–277. doi: 10.1097/CMR.0000000000000234

Figure 1.

Figure 1

Swim plot of treatment duration on study and reasons for discontinuation. Three patients obtained >16 weeks of clinical benefit. Patients came off for either POD (blue; n=9), toxicity (green; n=3), or pursuing immune-based therapy (orange; n=2).